- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00555529
Systemic Endothelial Abnormalities in COPD
Systemic Endothelial Abnormalities in COPD Measured by Radial Artery Applanation Tonometry (RAAP)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Patients with moderate and severe COPD (GOLD stage II and III) will be studied and their results will be compared with age-matched healthy non- smokers and smokers.
RAAP will be taken every 5 minutes for 15 minutes before salbutamol and every 5 minutes for another 15 minutes after salbutamol.
Several parameters of lipoprotein profiles, anti-oxidant plasma capacity, inflammatory cytokines, hormones, growth factors and vascular cell adhesion molecules will be studied in blood. In addition, several inflammatory and oxidative markers will be studied in exhaled breath condensate. Lung function and impulse oscillometry will be made to investigate airway resistance, and exhaled NO (nitric oxide) at different expiratory flows will be measured to assess alveolar and bronchial NO. Clinical assessment including dyspnoea and depression scores will also be made.
Undersøgelsestype
Kontakter og lokationer
Studiesteder
-
-
-
London, Det Forenede Kongerige, SW3 6LY
- National Heart and Lung Institute
-
London, Det Forenede Kongerige, SW3 6LY
- Imperial College London
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
• Male subjects with COPD with FEV1/FVC<70%; predicted defined as either stage moderate GOLD II (n=15) and severe GOLD III (n=7) diagnosis according to GOLD criteria (Global Strategy for the Diagnosis, Management, and Prevention of COPD) or Male subjects who are age-matched non-smokers (n=8) and male smokers (n=8) with normal lung function (FEV1>80%, FEV1/FVC>70%, n=8)
- Smokers:
An active smoker with a pack history of >10 pack years [number of pack years = (number of cigarettes per day / 20) x number of years smoked]. Smokers need to report the time when last cigarette was smoked (no less than 6 hours before the study visit).
- Patients will be allowed to use their current anticholinergic bronchodilators and continue on the dose of inhaled corticosteroids they are currently using. However they should refrain from short and long-acting β2-agonists for 6 and 12 hours, respectively, before the study visit.
- Aged 40 80 years inclusive
- Body mass index within the range 19-32kg/m2 inclusive
- FEV1 <15% reversibility (not % predicted) and an increase of <200ml after inhaled β2-agonists (400μg salbutamol).
- Capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Subject is available to complete the study.
Exclusion Criteria:
• As a result of the medical interview, physical examination or screening investigations, the Physician Responsible considers the volunteer unfit for the study.
- The subject has participated in a study with a new molecular entity during the previous 3 months or any other clinical trial during the previous 3 months. In case of a non invasive, clinical trial not involving new molecular entities a 2 week washout will be sufficient
- The subject regularly, or on average, drinks more than 21 units of alcohol per week.
- The subject has received oral steroids within 2 weeks prior to study entry.
- The subject has history of an upper respiratory infection (including sinusitis) within 2 weeks prior to study entry
- The subject has been hospitalised for a COPD exacerbation within 1 month of study entry.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
1
|
non-invasive tonometry
|
|
2
|
non-invasive tonometry
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Sergei A Kharitonov, MD PhD, Imperial College London
- Studieleder: Peter J Barnes, MD, Imperial College London
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 9022006
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .